Correction to Conflict of Interest Disclosure: In the Viewpoint titled “Tumor Mutation Burden—From Hopes to Doubts,” published online May 30, 2019, the Conflict of Interest Disclosures section was missing a disclosure statement for Dr Addeo. This article was corrected online.

Error in a Data Point in Table 3: In the Original Investigation titled “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies,” published in the April 2015 issue of JAMA Oncology, there was a typo in one of the data points of Table 3. This article was corrected online.

Errors in Data Presentation in Text, Figures, Table, and eTables: In the Original Investigation by Hilal et al titled “Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration,” published online May 2, 2019, in JAMA Oncology, there were errors in the number of US Food and Drug Administration approvals and trials described in the Abstract, Results, Discussion, and Conclusions sections; Figures, Table, and eTables. In Figure 1, 48 anticancer drug approvals were excluded, 95 drug approvals were reviewed, and 79 approvals were based on randomized clinical trials with optimal controls. The suboptimal control bars for genitourinary and lung/head and neck tumors in Figure 2 should reach 4% and 2%, respectively. In the Table, the study by Hussain et al has been added and the study by Kim et al has been deleted. In Supplement 2, the PROSPER trial was deleted from eTable 1 and added to eTable 2. The ALTA trial was deleted from eTable 2. This article was corrected online.

Correction to Conflict of Interest Disclosure: In the Viewpoint titled “Tumor Mutation Burden—From Hopes to Doubts,” published online May 30, 2019, the Conflict of Interest Disclosures section was missing a disclosure statement for Dr Addeo. This article was corrected online.

Error in a Data Point in Table 3: In the Original Investigation titled “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies,” published in the April 2015 issue of JAMA Oncology, there was a typo in one of the data points of Table 3. This article was corrected online.

Errors in Data Presentation in Text, Figures, Table, and eTables: In the Original Investigation by Hilal et al titled “Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration,” published online May 2, 2019, in JAMA Oncology, there were errors in the number of US Food and Drug Administration approvals and trials described in the Abstract, Results, Discussion, and Conclusions sections; Figures, Table, and eTables. In Figure 1, 48 anticancer drug approvals were excluded, 95 drug approvals were reviewed, and 79 approvals were based on randomized clinical trials with optimal controls. The suboptimal control bars for genitourinary and lung/head and neck tumors in Figure 2 should reach 4% and 2%, respectively. In the Table, the study by Hussain et al has been added and the study by Kim et al has been deleted. In Supplement 2, the PROSPER trial was deleted from eTable 1 and added to eTable 2. The ALTA trial was deleted from eTable 2. This article was corrected online.

Correction to Conflict of Interest Disclosure: In the Viewpoint titled “Tumor Mutation Burden—From Hopes to Doubts,” published online May 30, 2019, the Conflict of Interest Disclosures section was missing a disclosure statement for Dr Addeo. This article was corrected online.

Error in a Data Point in Table 3: In the Original Investigation titled “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies,” published in the April 2015 issue of JAMA Oncology, there was a typo in one of the data points of Table 3. This article was corrected online.

Errors in Data Presentation in Text, Figures, Table, and eTables: In the Original Investigation by Hilal et al titled “Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration,” published online May 2, 2019, in JAMA Oncology, there were errors in the number of US Food and Drug Administration approvals and trials described in the Abstract, Results, Discussion, and Conclusions sections; Figures, Table, and eTables. In Figure 1, 48 anticancer drug approvals were excluded, 95 drug approvals were reviewed, and 79 approvals were based on randomized clinical trials with optimal controls. The suboptimal control bars for genitourinary and lung/head and neck tumors in Figure 2 should reach 4% and 2%, respectively. In the Table, the study by Hussain et al has been added and the study by Kim et al has been deleted. In Supplement 2, the PROSPER trial was deleted from eTable 1 and added to eTable 2. The ALTA trial was deleted from eTable 2. This article was corrected online.